Outcome after high-dose radioiodine therapy for advanced differentiated thyroid carcinoma in childhood.
OBJECTIVE
To evaluate the clinical outcome in childhood patients receiving postoperative high-dose radioiodine therapy for advanced differentiated thyroid carcinoma.


METHODS
Patients under 18 years old with neck diseases (n = 4) or distant metastases (n = 10) received postoperative radioiodine ablation and repeated treatments for a median of 2 (0.8 10) years with an averaged activity of 25.0 (7.0 72.2) GBq.


RESULTS
Partial remission was achieved in 6, stable disease in 6 and progressive disease in 2 patients, without severe side effects except for two Grade 1 and one Grade 2 WHO haematological toxicity. The median survival time from diagnosis to the last treatment sessions was 5.3 (range, 0.7 14.5) years.


CONCLUSIONS
High-dose radioiodine treatment was well tolerated with satisfactory outcome in childhood patients with advanced differentiated thyroid carcinoma.
Gao
Yun-Chao
YC
Department of Nuclear Medicine, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China.
Lu
Han-Kui
HK
D000293:Adolescent; D002277:Carcinoma / Q000532:radiotherapy* / Q000601:surgery; D002454:Cell Differentiation; D002648:Child; D002675:Child, Preschool; D018450:Disease Progression; D004307:Dose-Response Relationship, Radiation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D012189:Retrospective Studies; D013964:Thyroid Neoplasms / Q000532:radiotherapy* / Q000601:surgery; D016896:Treatment Outcome
D007457:Iodine Radioisotopes